Clinical Trials Logo

Acute Lung Injury clinical trials

View clinical trials related to Acute Lung Injury.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06430619 Completed - Clinical trials for Respiratory Distress Syndrome, Adult

Can Novel Oxygenation Indices Guide the Diagnosis of Acute Respiratory Distress Syndrome

Start date: June 1, 2012
Phase:
Study type: Observational

This study aims to determine the cut-off values of the new oxygenation indices and further investigate their capabilities in diagnosing ARDS and predicting its severity in ICU. Additionally, the investigators aim to compare these results with conventional oxygenation and saturation indices.

NCT ID: NCT06332768 Completed - Clinical trials for Acute Respiratory Distress Syndrome

NIV Versus HFO Versus Standard Therapy Immediately After Weaning From Mechanical Ventilation in ARDS Patients

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

The weaning failure is a paramount challenge when aggressive discontinuation of respiratory support in ARDS. The aim of the study is to improve weaning safety and efficacy by a transient postextubation non-invasive respiratory support.

NCT ID: NCT06311448 Completed - Clinical trials for COVID-19 Acute Respiratory Distress Syndrome

Personalized Targeted Immunomodulation in COVID-19 ARDS

COMODULATE
Start date: March 2, 2020
Phase:
Study type: Observational

Rationale: In COVID19 single-targeted immunomodulation, mostly via an IL-6 receptor blocker, was used by a one-size fits all non-targeted approach. In future pandemics the same might occur. However, for individual patients, this might not yield optimal treatment. Objectives: This project aims to identify a way to individualize and target immunomodulation, using COVID19 as a testcase for the future. - Identify immunological pathways which are associated with outcome in C-ARDS. - Test whether an individualized biomarker-based approach has an effect on outcome and costs when using single-target immunomodulation in C-ARDS(Tocilizumab, Anakinra, etc.). - Explore whether other immunological pathways were present in patients with C-ARDS which could have been intervened with medication which is already available and has been described in ARDS or similar diseases. Study type: Retrospective observational multicenter study in the Netherlands. Study population: Adult patients (≥ 18 years) hospitalized and admitted to the ICU with COVID-19 and acute respiratory distress syndrome (ARDS) (i.e., receiving invasive mechanical ventilation) will be included. Intervention (if applicable): Not applicable (retrospective study design). Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Given the retrospective nature of the study, no burden, risks or benefits for the patient are associated with participation. The target population of this study is specific to hospitalized patients with COVID-19.

NCT ID: NCT06224010 Completed - Clinical trials for Mechanical Ventilation Complication

Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS

Start date: November 21, 2020
Phase:
Study type: Observational

Data comparing respiratory drive and effort in critically ill patients with acute respiratory distress syndrome associated to different severity of COVID-19 penumonia (CARDS) and to other risk factors are lacking. Objectives: To assess respiratory drive and effort of CARDS patients at the first transition from controlled to assisted spontaneous breathing. The second aim was the rate of a composite outcome including the need of higher level of sedation

NCT ID: NCT06199141 Completed - Clinical trials for Respiratory Distress Syndrome, Adult

Multi-drug Resistant Gram-negative Bacteria and Veno-venous Extracorporeal Membrane Oxygenation (ECMO)

MDR-ECMO
Start date: January 1, 2017
Phase:
Study type: Observational

Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is a life-support technique used in patients with most severe acute respiratory distress syndrome (ARDS). ARDS is a life-threatening form of respiratory failure associated with a mortality rate of approximately 40-45%.Despite several studies confirming a real benefit of the use of ECMO in patients with ARDS who are unresponsive to conventional management, ECMO is still a complex and costly treatment that can be exposed to potential complications, such as nosocomial infections (NI).

NCT ID: NCT06159465 Completed - Respiratory Failure Clinical Trials

Utility of Defining ARDS and Past and Current Definitions of ARDS

Delphi_ARDS
Start date: December 13, 2023
Phase:
Study type: Observational

Acute Respiratory Distress Syndrome (ARDS), marked by acute hypoxemia and bilateral pulmonary infiltrates, has undergone multiple definitions over the years. Challenges persist regarding the ARDS definitions, leading to various revisions. Through the Delphi study, the investigators aims to gather global opinions on the conceptual framework of ARDS, assess the utility of current and past definitions, and explore the role of subphenotyping. The diverse panel's collective expertise will contribute valuable insights for refining future ARDS definitions and enhancing clinical management.

NCT ID: NCT06134674 Completed - Clinical trials for COVID-19 Acute Respiratory Distress Syndrome

Early Versus Delayed Enteral Nutrition in Critically Ill Adults With COVID-19

Start date: October 20, 2021
Phase:
Study type: Observational

The goal of this observational study is to determine the relationship between the nutritional profile of critically ill patients diagnosed with COVID-19 and disease severity, prognosis, and survival, to assess the ability to meet nutritional goals, EN complications, and reasons for discontinuation and postponement of feeding. The main questions aim to answer are the relationship between the duration of EN initiation and Prognostic Nutritional Index (PNI) score, neutrophil-lymphocyte ratio (NLR), oxygenation status, MV, ICU, and length of hospital stay, overall mortality, and whether nutritional goals were met, EN complications, and reasons for discontinuation and postponement.

NCT ID: NCT05993377 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Prediction of Duration of Mechanical Ventilation in ARDS

PIONEER
Start date: August 14, 2023
Phase:
Study type: Observational

The investigators are planning to perform a secondary analysis of an academic dataset of 1,303 patients with moderate-to-severe acute respiratory distress syndrome (ARDS) included in several published cohorts (NCT00736892, NCT022288949, NCT02836444, NCT03145974), aimed to characterize the best early scenario during the first three days of diagnosis to predict duration of mechanical ventilation in the intensive care unit (ICU) using supervised machine learning (ML) approaches.

NCT ID: NCT05954351 Completed - Clinical trials for COVID-19 Acute Respiratory Distress Syndrome

PRactice of Ventilation and Adjunctive Therapies in COVID-19 Patients.

PRoVAcT-COVID
Start date: May 1, 2022
Phase:
Study type: Observational

PRactice of Ventilation and Adjunctive Therapies in COVID-19 Patients. An observational study of ventilation practice and adjunctive therapies in critically ill, invasively ventilated COVID-19 patients during the first and second surge of COVID-19 in the Netherlands.

NCT ID: NCT05946525 Completed - Clinical trials for Respiratory Distress Syndrome

Ventilatory Variables in Subjects With Acute Respiratory Distress Syndrome Due to COVID-19

Start date: February 10, 2023
Phase:
Study type: Observational

Research question: Are the ventilatory variables related to mechanical power associated with the outcome of subjects who received mechanical ventilation (MV) for Acute Respiratory Distress Syndrome (ARDS) secondary to pneumonia (NMN) due to COVID-19?